Effect of Gabapentin, Amitriptyline and Pregabalin in Neurological, Sciatica and Orthopaedic Backpain Patients

Bhupesh Bhardwaj[1], Rohit Kumar Juneja[2], Ms. Sushma Sharma

[1] *Student Of M. Pharmacy, School of Pharmacy and Emerging Sciences, Baddi University of Emerging Sciences and Technology, Himachal Pradesh, India*

[2] *Student Of M. Pharmacy, School of Pharmacy and Emerging Sciences, Baddi University of Emerging Sciences and Technology, Himachal Pradesh, India*

[3]*Faculty of Pharmaceutics, School of Pharmacy and Emerging Sciences, Baddi University of Emerging Sciences and Technology, Himachal Pradesh, India*

ABSTRACT

Neuropathic pain is a complex and debilitating condition affecting a wide range of patients.. Sciatica is a common condition affecting a diverse range of individuals, particularly those in middle age, physically demanding jobs, or with certain lifestyle factors. Understanding its causes, symptoms, and affected populations helps in the effective management and treatment of this painful condition, often requiring a multidisciplinary approach to ensure relief and prevent recurrence. Orthopaedic back pain is a widespread issue that affects a diverse population, particularly those in middle age, physically demanding occupations, or with certain lifestyle factors. Understanding the causes, symptoms, and demographics helps tailor effective management strategies, combining self-care, physical therapy, medication, and in some cases, surgical intervention to alleviate pain and improve quality of life. Pregabalin, amitriptyline, and gabapentin can be effective for such conditions, their use is surrounded by controversy due to issues related to safety, efficacy, and potential for misuse. Careful consideration and adherence to guidelines are essential when prescribing these medications to mitigate risks and ensure patient safety. The safety profiles of these medications are a significant concern, particularly regarding their potential for serious side effects and interactions with other drugs. The potential for misuse and dependence is a major issue, especially with pregabalin and gabapentin. This has led to tighter regulations and increased monitoring of prescriptions. In response to misuse, some regions have implemented stricter guidelines for prescribing these medications, including reclassification to controlled substances. In this article various studies and clinical research done on the use of these three drugs in pain management is enlisted, this article will help in proper use and prescribing patterns of these drugs.

Keyword:- *sciatica, neurological pain, orthopaedic backpain , amitriptyline, use of pregabalin and gabapentin*

1. INTRODUCTION

Neurological patients are the individual who experience health issues related to their nervous system, which includes the brain, spinal cord, and peripheral nerves. These conditions also vary widely, ranging from neurological disorders like epilepsy, multiple sclerosis, or Parkinson's disease to traumatic brain injuries or strokes. In Hospitals, Healthcare professional together to provide treatment for Neurological Patients, and recognise the needs of neurological patients, including their emotional and social wellbeing. Neurological patients go on a journey filled with various treatments aimed at managing their illness and improving their quality of life [1]. Sciatic diseases primarily refer to conditions that cause sciatica, which is characterized by pain that radiates along the path of the sciatic nerve. The sciatic nerve is the longest nerve in the body, running from the lower back, through the hips and buttocks, and down each leg. Sciatica is not a disease itself but a symptom of underlying medical conditions that affect the sciatic nerve. The treatments can include a diverse range of approaches, ranging from medications and therapies to surgeries and lifestyle modifications. Numerous neurological conditions are managed with the help of medications, which play a central role in the treatment process[2]. In case of Epilepsy,

Patients are prescribed antiepilepsy drugs to manage seizures while people with Parkinson's disease may benefit from medications that regulate dopamine levels in the brain to alleviate motor symptoms caused by the disease. In addition to reducing symptoms, these medications also aim to slow the progression of the disease and improve the overall well-being of the patient. Neurological patients also receive the pharmacological involvements and personalised therapies. In order to address mobility concerns, improve motor function, and improve communication skills, certain therapies such as physical therapy, occupational therapy, and speech therapy are commonly used. The goal of these therapies is not only to optimize physical abilities, but also to empower patients and help them regain independence and be more engaged in their daily lives in a meaningful way. To address neurological conditions that are refractory to other treatments, surgeries may sometimes be necessary for complete treatment. Sometimes, when medicines and other treatments don't work, surgery is required in treatment of the disorder. Beyond medical and surgeries, lifestyle modifications do play a crucial role in management of neurological conditions. This may include adopting a healthy lifestyle including healthy diet, engaging in regular exercise, managing stress, and getting adequate rest. These lifestyle changes complement medical treatments and also empower patients to take an active role in their own care and promote overall well-being. Orthopaedic back pain refers to pain originating from the musculoskeletal structures of the back, including bones, muscles, ligaments, and intervertebral discs. It is a prevalent condition that affects a significant portion of the population at some point in their lives, leading to discomfort, disability, and a substantial impact on quality of life.

2. OVERVIEW OF SOME DRUGS USED IN NEUROLOGICAL, SCIATIC AND ORTHOPAEDIC BACKPAIN PATIENTS

2.1 Gabapentin

Gabapentin is a medication prescribed for managing many neurological conditions. It belongs to a class of drugs called anticonvulsants, which means it's primarily used to prevent seizures. Gabapentin is used as the first choice for treatment of long-term nerve pain by many medical professionals[3]. This recommendation applies to most types of nerve pain, except for trigeminal neuralgia, where it might be used as a second or third option[4]. Studies have shown that gabapentin can help in pain management in some people with postherpetic neuralgia (pain after shingles) and diabetic neuropathy (nerve damage from diabetes)[5]. In the United States, it's approved for treating postherpetic neuralgia. European guidelines also suggest gabapentin can be effective for central pain, which includes conditions like fibromyalgia.

It is also effective in treatment of other neurological conditions, such as neuropathic pain, restless legs syndrome, and certain types of nerve-related pain[6]. Gabapentin is prescribed for neurological patients, to alleviate symptoms like chronic pain, tingling sensations, or uncomfortable muscle spasms[7]. This medication works by relaxing overactive nerve signals in the brain and spinal cord, which can help reduce pain and improve overall comfort. Gabapentin is a type of medicine prescribed to help control seizures and ease nerve pain. Gabapentin is commonly prescribed to manage different kinds of discomfort, like the nerve pain linked with conditions such as diabetic neuropathy or postherpetic neuralgia[8]. For patients dealing with these painful conditions, gabapentin can be a crucial in their treatment plan, offering much-needed relief and improving their quality of life. Research indicates that around 30-40% of people treated with gabapentin experience decent pain relief (at least 50%) or report feeling "greatly improved" compared to those who take a placebo.

However, gabapentin doesn't seem to help much in case of chronic low back pain or sciatica, and it's not effective for nerve pain caused by HIV or cancer.

Gabapentin is available in tablet, capsule, and oral solution forms, making it convenient for patients to take as directed by their healthcare provider. It is important for patients take this medication exactly as prescribed and not adjusting the dosage without consulting their doctor provider first. Gabapentin also may cause side effects in some patients such as dizziness, drowsiness, fatigue, and difficulty with coordination. However, many people tolerate gabapentin well, and these side effects often improve over time as the body adjusts to this medication. Gabapentin can be an effective solution in managing neurological conditions and improving quality of life for patients. Gabapentin undergoes little or no metabolism. With careful monitoring it can help alleviate symptoms and support patients in living more comfortably with their condition[9].

Gabapentin most common side effect include sleepiness, dizziness, fatigue, ataxia, peripheral edema , and nystagmus and weight gain . Serious side effects are respiratory depression, allergic reaction. Lower doses of Gabapentin are recommended for patients with kidney disease. Serious side effects are inflamed pancreas, hallucinations, anaphylaxis, respiratory depression, and increased suicidal ideation. Gabapentin use is associated with 40 percent increased od suicide and suicide attempt and this this risk even greater for bipolar disorder patients. When combined with opiods, benzodiazepines and other depressants result in respiratory depression.

Gabapentin gets absorbed from the intestines with oral bioavailability of 80 percent in 100 mg dosage form. But bioavailability decreases to 60% at 300 mg, 47% at 400 mg, 34% at 800 mg, 33% at 1,200 mg, and 27% at 1,600 mg, all with the same dosing schedule as with 100 mg dosage form.

Gabapentin at a low dose of 100 mg has a Tmax (time to peak levels) of approximately 1.7 hours, while the Tmax increases to 3 to 4 hours at higher doses. Food does not significantly affect the Tmax of gabapentin and increases the Cmax and area-under-curve levels of gabapentin by approximately 10%.

Gabapentin can easily cross the blood–brain barrier and enter the CNS. Gabapentin concentration in cerebrospinal fluid is approximately 9–14% of its blood plasma concentration. Gabapentin due to its low lipophilicity, requires an active transport across the blood–brain barrier[10]. The LAT1 is highly expressed at the blood–brain barrier and transports gabapentin across into the brain[11]. In case of intestinal absorption mediated by an amino acid transporter, the transport of gabapentin across the blood–brain barrier by LAT1 is saturable. Gabapentin does not bind to other drug transporters such as P-glycoprotein (ABCB1) or OCTN2 (SLC22A5). It is not significantly bound to plasma proteins (<1%).

Gabapentin is eliminated renally in the urine. Gabapentin has short elimination half-life, with the average value of 5 to 7 hours. Because of its short elimination half-life, gabapentin must be administered 3 to 4 times per day to maintain therapeutic levels[12]. Gabapentin XR (brand name Gralise) is taken once a day.

When gabapentin is taken excessively , it can make them feel really good - like they're euphoric or in a calm, relaxed state. Some people even compare it to the high they get from marijuana. They might feel more sociable and have fewer cravings for alcohol or cocaine. Unfortunately, in recent years, there's been an increase in people abusing gabapentin to get these pleasurable effects.

From 2013 to 2017, there was a rise in cases of gabapentin misuse, overdose, and even people trying to harm themselves with it in the United States. So, while gabapentin can be helpful when used as prescribed, it's essential to be aware of the risks of taking too much of it.

2.2 Pregabalin

Pregabalin is anticonvulsant drug used for the treatment of epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, opioid withdrawal, and generalized anxiety disorder (GAD). It is used in epilepsy as an adjunctive treatment for partial seizures. It works by blocking specific calcium channels. Pregabalin may be used in conjunction with the other medications for treatment of drug-resistant focal epileptic seizures. When used alone, it is less effective than some other seizure drugs and It's uncertain how it compares to gabapentin for this application. Pregabalin is recommended by the European Federation of Neurological Societies as a first-line medication for treatment for pain caused by diabetic neuropathy, post-herpetic neuralgia, and central neuropathic pain. [3]However, only a small number of people benefit significantly, whereas the majority do not benefit much. As a first-line drug, it is accorded the same weight as gabapentin and tricyclic antidepressants; however, the latter are less expensive in 2010. Pregabalin is just as efficient in relieving pain as amitriptyline. The combination treatment of pregabalin with amitriptyline or duloxetine provides extra pain relief for patients whose pain with one medication is not relieving[13]. Higher doses of pregabalin have been found in studies to be more effective. The use of pregabalin in cancer-related neuropathic pain remains debated, despite the fact that it is used frequently. It has been studied for the prevention of post-surgical chronic pain, although its effectiveness in this regard is still doubtful. Pregabalin is generally not considered effective in the treatment of acute pain and Pregabalin had no effect on overall pain levels in trials assessing its effectiveness for the treatment of acute post-surgical pain, while participants used less morphine and experienced less opioid-related side effects.

Pregabalin is absorbed in the intestines by a transporter called LAT1. Pregabalin, unlike gabapentin, transports via several carriers in addition to LAT1 [14].While gabapentin absorption usually varies by dose, pregabalin absorption is similar across various doses[15]. Pregabalin has a high oral bioavailability, with more than 90% of the dose absorbed irrespective of food consumption. On an empty stomach, its absorption is even rapid, reaching peak levels within an hour. Food may initially inhibit absorption, resulting in delayed peak levels while having no effect on overall absorption.

Common adverse effects include headaches, dizziness, tiredness, confusion, memory loss, poor coordination, dry mouth, eyesight issues, and weight gain[16]. Serious side effects include angioedema, drug abuse, and an increased risk of suicide[17, 18]. Despite its relaxing and anti-seizure effects, it can cause seizures in high dosages. And also there are reports of impaired vision, increased hunger, memory issues. Some very rare side effects include sadness, hallucinations, and muscle cramping[19]. It can occasionally cause noteworthy complications such as heart attacks or pancreatitis. Additionally, recreational usage has been linked to negative effects[20]. The FDA recommended that new warnings about the risk of respiratory depression to be included in gabapentinoids'

prescribing instructions[21]. And FDA also instructed drug producers to conduct clinical trials for further analysis of their abuse potential, particularly when combined with opioids co-use may raise the risk of respiratory depression[22].

Among 49 case reports filed to the FDA throughout the five-year period from 2012 to 2017, twelve patients died from respiratory depression due to gabapentinoids, all of them had at least one risk factor.

The FDA examined the outcomes of two randomised, double-blind, placebo-controlled clinical trials in healthy humans, three observational studies, and multiple animal studies. One study found that using pregabalin alone or in combination with an opioid pain medication can impair respiratory function. The other trial found that gabapentin alone increased pauses in breathing when sleeping. Three observational studies at one academic medical centre found a link between gabapentinoids administered prior to surgery and respiratory depression developing after various types of procedures. The FDA also observed at multiple animal studies that pregabalin medication alone and pregabalin in combination with opioids can impair respiratory function.

2.3 Amitriptyline

Amitriptyline is an FDA-approved drug for treatment of major depressive disorder (MDD) in adults. It is used for treatment and management of Anxiety, post-traumatic stress disorder, insomnia, chronic pain (diabetic neuropathy, fibromyalgia), irritable bowel syndrome, interstitial cystitis (bladder pain syndrome), migraine prophylaxis, postherpetic neuralgia, and sialorrhea which are among the non-FDA authorised suggestions. Amitriptyline has been used to treat post-COVID headache. Amitriptyline is a medication that is used for reducing the discomfort caused by diabetic nerve damage. It is frequently advised as one of the initial or secondary therapies for this type of pain. While it is as effective as any other medications such as gabapentin and pregabalin, some people may find it more difficult to handle. Combination of amitriptyline and pregabalin can provide better effect for patients who are still experiencing pain after taking just one medication. Amitriptyline can also be used to numb specific nerves, making it useful for local anaesthesia. Low doses of amitriptyline can help with fibromyalgia by relieving pain and fatigue and improving sleep. It is optional alternative, particularly for fibromyalgia and depression. Amitriptyline can be used in combination with other medications such as fluoxetine or melatonin to treat fibromyalgia pain more effectively. Although there is limited evidence, amitriptyline may help relieve pain in some cancer patients, particularly when other medications such as opioids do not give complete relief. It is indicated as a second alternate for certain types of nerve pain that are not induced by chemotherapy where opioids are unsatisfactory. Amitriptyline can also be used for treatment of disorders such as atypical facial discomfort and nerve pain in multiple sclerosis. It is widely used to relieve burning or stabbing feelings in the arms and legs which caused due to brain and spinal cord injury. Amitriptyline is a tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine neurotransmitters. Tricyclic antidepressants' core structure consists of a three-ring central structure and a side chain. Amitriptyline is a tertiary amine with high affinity for alpha-adrenergic, histamine (H1), and muscarinic (M1) receptors. Amitriptyline excites noradrenergic or serotonergic neurotransmission by inhibiting the norepinephrine or serotonin transporter (NET or SERT) at presynaptic terminals. Chronic amitriptyline treatment desensitises presynaptic auto receptors and heteroreceptors, resulting in long-term alterations in monoaminergic neurotransmission. Amitriptyline is more sedative and has stronger anticholinergic effects than other TCAs. The start of therapeutic activity, like that of other antidepressants, normally occurs between 2 to 4 weeks. Amitriptyline is well absorbed when used orally. However, only 30 to 60% of the dose reaches the bloodstream as the liver breaks it down before it can reach the rest of the body. Once in the bloodstream, amitriptyline circulation is rapid throughout the body, with a significant amount ending up in tissues and organs. It can even transfer from a pregnant woman's bloodstream to her foetus. Certain enzymes in the body convert amitriptyline to nortriptyline. These enzymes, CYP2C19, CYP3A4, and CYP2D6, help the body break down and eliminate amitriptyline. Amitriptyline has effects lasting between 10 and 28 hours.

Amitriptyline is effective in treatment of depression, although it is rarely used as a first-line antidepressant because it has increased toxicity in overdose and also has poor overall acceptability. It can be used as a second-line therapy for depression when previous treatments have failed. For treatment-resistant teenage depression or cancer-related depression, amitriptyline is not effective, however the number of patients treated in both studies was modest. It is sometimes also used for treatment of depression in Parkinson's disease, but there is lack of much evidence to support this.

The side effects of amitriptyline include dry mouth, sleepiness, dizziness, constipation, and weight gain. Other regular but less common side effects are headaches, blurred vision, a rapid heartbeat, increased appetite, shaking, feeling fatigued or slowed down, and stomach trouble. Also Some may find having difficulty in urinating, however this is less common, occurring in approximately 8.7% of users. Amitriptyline has been also linked to increased

suicidal ideation, people under the age of 24. In some situations, amitriptyline may produce reasonable liver test abnormalities in 10-12% of users, but these are usually minor and resolve on their own. A small number of patients may have consistently high liver enzymes, but clinically significant liver issues are uncommon. However, amitriptyline is considered to have a slightly higher risk of liver problems than other antidepressants. Amitriptyline by relaxing can potentially alter the electrical activity of the heart, resulting in a uncertain extension of the QT interval. This isn't normally an issue at regular doses, but it can be severe effect in cases of overdose.

3. EFFECT OF PREGABLIN, GABAPENTIN AND AMITRIPTYLINE IN NEUROPATHIC PAIN MANAGEMENT

Pregabalin is the first medication approved by the FDA for treating the nerve pain and post-herpetic neuralgia. Both animal and human studies have found out that it's effective in management in this type of pain. Pregabalin works by affecting certain nerve pathways in the body, which help in reducing pain and related symptoms. One of its main advantages is that it's reliable, easy to use, and generally well tolerated by patients.

Gabapentin is another medicine usually used for post-herpetic neuralgia. It works by binding to certain channels in the nervous system, which helps in reducing the nerve cell excitability and decrease pain signals.

Amitriptyline is another type of antidepressant used for treatment of chronic nerve pain. Its exact mechanism of action for pain relief isn't completely understood, but it's believed that it causes changes in serotonin and noradrenaline levels in the brain of the patient. While it may take a few weeks to notice its full benefits, any side effects usually lessen over time.

3.1 Studies and clinical trials

This study[23] examines the safety and effectiveness of three generally prescribed medicines for neuropathic pain which are Gabapentin, Pregabalin, and Amitriptyline respectively. Following a Thorough analysis of an existing literature and clinical studies. this review aims to provide understandings of the relative efficacy and side effects of these drugs. Based on a randomized study including 300 patients identified with chronic lumbar radiculopathy, the review highlights decent pain relief observed across all the treatment groups. And it also notes that Pregabalin gives decent advantages in Numeric pain rating scale (NPRS) scores, while Gabapentin had reported serious side effects such as dizziness and sedation as compared to Pregabalin and Amitriptyline. The findings in this study suggest that while all three medications are effective in management of NeP, Gabapentin may offer better long-term patient compliance due to its favourable safety profile.

According to this study[24], Neuropathic pain, is very common and persistent condition, which cause difficulty in treatment due to its wide-range causes and symptoms. Even with its high frequency, there is still very limited data available on neuropathic pain drugs prescription in Lebanon. This study aimed to understand the pattern of prescribing for treatment in the Lebanese adults with neuropathic pain. Over the period of 10 months, the researchers surveyed around 360 adults with neuropathic pain at 30 different community pharmacies, gathering information on prescribed medicines, and faithfulness to treatment procedures. Results disclosed that most patients received the suggested first-line drugs, with the pregabalin being the mostly prescribed medicine. Combination of these medicines were common, reflecting the complexity of management of neuropathic pain. Overall, the study do suggests that neuropathic pain management in Lebanon is in accordance with international guidelines, emphasizing the importance of Individualized treatment approaches for effective treatment of Neuropathic pain.

In this another study [25], researchers set out to examine the prescription patterns of medicines used in the treatment of the cancer-related neuropathic pain (CRNP) and to assess how much physicians followed the guidelines which are given by the Neuropathic Pain Special Interest Group (NeuPSIG). The cross-sectional observation research done at a tertiary care hospital's pain and palliative care outpatient clinic; the researchers recruited patients with CRNP who had been screened. Data collected was demographic information, diagnosis, prescribed medicines, and faithfulness to NeuPSIG guidelines. The 300 patients were screened, which were 64% male along with 36 percent, with an average age of 48.26± 13.05 years, and symptom were pin-and-needle sensations. The Head-and-neck cancers were the most common diagnosis. Amitriptyline and Pregabalin have emerged as the mostly prescribed medicines for CRNP, and meanwhile tapentadol, not recommended by NeuPSIG, is still frequently prescribed also. And substantial number of prescriptions donot fully follow the NeuPSIG guidelines. Overall, the findings underlined the need for greater faithfulness to established guidelines in managing CRNP.

According to this study [26]The UK government reclassified gabapentin and pregabalin as 'controlled drugs', leading to research to modifications in prescribing patterns for these medicines before and after regulatory change. Using data available from the UK Clinical Practice Research Datalink, which collects primary care health records nationally, this research lead to investigating the new and existing prescriptions for gabapentin and pregabalin from their approval in the UK until September 2019. Month to month prescribing rates were analysed from October 2017 to September 2019, with the aid of the statistical methods used to assess changes in prescription pattern over time. The study also discovered the reasons behind prescription of these medicines, previous pain-related prescriptions, and also the coexisting prescriptions for other medicines along with gabapentinoids. Research revealed that while the new gabapentin prescriptions increased annually until 2016-17 before declining, new pregabalin prescriptions were at peak in 2017-18 and had negligible decrease until 2019. The number of prescriptions for both medicines increased annually until 2017-18 and 2018-19, after which they stabilized. Gabapentinoids were commonly prescribed along with opioids, antidepressants, benzodiazepines, and Z-drugs. The research concluded that number of gabapentinoid prescriptions has begun to decline, the exact impact of reclassification on overall prescription remains undetermined. The small change in existing gabapentinoid prescriptions after reclassification will have no sudden impact on current prescribing patterns.

In this study[27], researchers looked at the treatment of neuropathic pain cases at Siriraj Pain Clinic. This research included patients diagnosed with neuropathic pain between a period of one year from January 2008 and June 2009. In this research patients were divided into two groups: pure neuropathic pain and mixed neuropathic pain, and examined their features, conditions, neuropathic pain kinds, and treatments used. The research included 266 patients who were analysed and constituted of females (57%) with average age of 56 y ears. Musculoskeletal disorders, cancer, and hypertension were identified as common complications. Peripheral nerve compression emerged as the primary cause Among the different reasons. Gabapentin, tramadol, and amitriptyline were used in the management and treatment, and highlighted importance of use of these medicines in combination.

According to this study[28], The purpose of this study was to provide insight on the clinical features and healthcare utilisation patterns of patients with neuropathic diseases (PNDs) which requires treatment by general doctors in the United Kingdom. Using data from a large computerised UK database, person aged 18 and above who attended doctors with diagnosis of PND between jan 1, 2006 and December 31, 2006 were identified as PND patients. These patients were than compared to an equal number of randomly selected individuals who saw their doctors over the same time period but made no mention of PND. The analysis consisted of 31688 PND patients with a mean age of 56 years and 62 percent female. And patients showed a higher frequency of several medical conditions. PND patients had more occurrence of several medical conditions, like digestive diseases, circulatory disease, and depression, than the control group. PND patients were prescribed more pain-relieving medicines such as NSAIDS, opioids, tricyclic antidepressants, and antiepileptics. The data obtained from research highlighted the high use of pain related medicines among PND patients in the UK.

In this study[29], recent assessment of multiple 38 studies were done. The study included comparison of the pregabalin and placebo. This study concluded that 20 adverse events were associated with Pregabalin medicine. This time, researchers wanted to examine if the Adverse effects will vary according to persons individual health disorder being treated with Pregabalin. Researchers reviewed the same 38 trials again, but this time focus was on those in which pregabalin administration was at a level of 600 mg per day. The trials were divided into four categories based on the health conditions they were investigating: neuropathic pain, drug-resistant partial epilepsy, mental disorders and fibromyalgia. And used a method called as risk differences (RDs) to observe how many people had to stop Pregabalin medication due to Adverse Effects than those on placebo, as well as frequency of the 20 Adverse effects that happened in the four distinct health situations. The investigation included 22 of these trials. This led to discovery with the exception of ataxia, the rates of people quitting Peragablin because of Adverse Effects and the occurence of the majority of peragablin adverse effects were similar across all the four health conditions investigated. When researchers looked specifically at people who were given a placebo, they discovered that some adverse effects related to the vestibulo-cerebellar system (such as ataxia, diplopia, and impaired vision) were further common in drug-resistant partial epilepsy as compared to other health conditions. Epilepsy was associated with more diplopia and blurred vision than neuropathic pain, as well as more ataxia than anxiety disorder and fibromyalgia. In other adverse effects of the central nervous system (CNS), somnolence was more common in epilepsy as compared to neuropathic pain and anxiety disorders, although asthenia was more common in epilepsy than in fibromyalgia. Conclusion is while the drug-resistant partial epilepsy increases the chance of acquiring some vestibulo-cerebellar adverse effects, the overall risk of peragablin producing toxicity is not different in varied health states.

In this study[30], Pregabalin is used in the management and treatment of neuropathic pain, still patients may not fully receive the benefits from this medication because doctors may start with low doses or increase the dose too early. This study discourses how to properly start, alter, and manage pregabalin treatment, and issues of driving

safety and risk of misuse. It is recommended to start with a low dose and than gradually increase it to minimize the adverse effects and guarantee patients health and well being. During increasing the dose, it is generally recommended to start administration of higher dose in the evening. It is very critical for patients to have realistic expectation of how long it will take for pregabalin to function and any side effects, so they can have personalized treatment.

According to this study[31], Antiepileptic drugs are used widely for nuerological and mental disorders but there is no complete and detailed of all research on any one specific antiepileptic drug tolerance. So researchers reviewed all available trials on pregabalin, frequently used in treatment of epilepsy to discover any associated side effects. Researchers also wanted to find any major side effects with pregabalin use, and also if the effects varied according to the dose. All medical databases and other sources for research involving adults consuming pregabalin for any health problem that were published before February 2010 were searched. These studies needed to be double-blind trials which involved comparison of pregabalin with a placebo, including at least 20 participants in each group and lasting minimum of 4 weeks. After careful evaluation of these trials, it was determined that which side effects were linked with pregabalin and statistical methods were utilized for assessment of the strength of this relationship and how it translated in dosage adjustments. In analysis of 38 trials, it was discovered that out of 20 from total of 39 identified adverse effects were considerably related with pregabalin use, which included dizziness, blurred vision, and fatigue, and cognitive and coordination impairments highly associated. Unexpectedly, major adverse events were not strongly linked with pregabalin. We also discovered that adverse effects were dependent upon dose, suggesting that some may be more common at lower levels. These findings highlight the implication of carefully monitoring for adverse effects, mainly those affecting cognitive function and coordination, and evaluation of multiple dosage levels when treating pregabalin.

In this study[32], the increasingly widespread availability of Gabapentin and pregabalin in recent years, has led to raising concerns about abuse and overdose dangers. The evaluation of 106 research has found there no evidence of any addictive properties, predominantly in people without a history of substance abuse. Pregabalin has increased addiction potential, predominantly between people with drug use disorders. The overdose on gabapentinoids is considered normally harmless, but mixing them with other drugs, like opioids and sedatives, can be lethal. These conclusions stress the importance of identification and comparisionof the addiction risks of gabapentin and pregabalin.

According to this study[33], the objective was to check the prescription and use of the pregabalin was responsible without any abuse. The analysis of data from 10,000 patients with prescribed pregabalin in healthcare. This led to the discovery that many patients, predominantly women of ages around of 62, were consuming pregabalin for the treat approved disorders. Though, many people had been using it for treatment and management of the bone and joint pain and fibromyalgia, which are not formally permitted purposes. Most patients had began using pregabalin without prior to using any other indicated drugs, and many had received greater doses than recommended, predominantly people with kidney problems. These data specify that improvement can be in the prescription of pregabalin.

In this study in Sweden[34], the evaluation of treatment method for pain along with pain medications in Western Sweden, evaluating for the 840,000 patient records ranging from 2004 to 2009. Most of the patients had discontinued the treatment in 3 to 6 months, using drugs: amitriptyline, pregabalin, and gabapentin. Only Few patients explored alternate medicines, highlighting the need for new medicines and better treatment approaches. Some of the patients who had undergone treatment for nerve pain also developed neuropathy or miscellaneous discomfort. Furthermore, a negligible portion of people had epilepsy, whereas a large proportion had mood disorders. The findings emphasises the significance of improving long-term management for chronic pain patients.

In this study[35], study of the use of antiepileptic drugs in diabetic polyneuropathy patients in Germany through a course of five-year. The Data collected from 48,324 people aging from 18 to 80 were analysed, concluding that 16.4% got antiepileptic drugs over this time, with pregabalin, gabapentin, and carbamazepine being the mostly used drugs for treatment. These Factors such as depression, gender, health insurance, general practice care, high HbA1c levels, prior neurological hospitalisations have been linked to antiepileptic drug use. Despite all these, antiepileptic drug usage was nonetheless rare among newly diagnosed diabetic polyneuropathy patients in Germany. More research is required to determine the reasons behind this low utilisation.

According to this study[33], they examined at pregabalin usage patterns along with the motive of improvement of the medical procedure, especially for off-label usages. In time period of April 2014 to January 2015, collected data from 10,155 patients at the 53 c medicalcare centres in Germany were analysed. Researchers found that pregabalin was frequently used off-label, usually for bone and joint pain and fibromyalgia. Unexpectedly, many patients started using pregabalin treatment before using suggested first-line medications such as amitriptyline or gabapentin. Also, a noteworthy proportion of people with kidney problems were prescribed higher-than-

recommended doses. These conclusions highlight the need for improvement of diagnosis as well as prescribing pattern in take full advantage of treatment results and ensuring proper moral medicine usage.

According to this study[36], Neuropathic pain disturbs a large percentage of the population, although the way it is diagnosed and treated varies by group. In Colombia, we sought to understand the management and costs of neuropathic pain from symptom start to two years after diagnosis. Analysing data from an insurance database, we discovered 624 patients in 49 cities, the majority of whom were around 50 years old and slightly more male than female. The most prevalent kind is lumbosacral radiculopathy, which is normally diagnosed within 90 days. Many patients underwent diagnostic tests, and the majority received first therapy from their general practitioner. Initial therapies frequently comprised medications that were not traditionally indicated as first-line alternatives, and combination therapy was prevalent. The average cost of care per patient over two years was around US$246.3.

In this study[37], investigation of gabapentin's pharmacology and effectiveness in treatment of neuropathic pain, highlighting its antihyperalgesic effects. Gabapentin, is not a central pain reliever, improves GABA production, and blocks non-NMDA receptors, and binds to the α2δ subunit of voltage-dependent calcium channels, reducing the excitatory neurotransmitter release. The clinical trials have confirmed gabapentin's effectiveness in a diversity of neuropathic pain syndromes, with patients getting an average pain score reduction of 2.05 points as compared to 0.94 points with a placebo on an 11-point scale. Around 30% of patients gained more than 50% pain reduction, still others may experience minor side effects such as dizziness as well as sleepiness. Gabapentin in combination with opioids may lead to an increased response rates, mainly in cancer-related neuropathic pain, due to its synergistic effects.

In this study[38], researchers examined how gabapentin could impact pain and opioid use. This research was conducted at two hospitals of southeastern Michigan and also involved evaluation of patients who had been taking gabapentin for at least 30 days. Gabapentin substantially reduced pain scores in the neuropathic pain group, especially in people with postherpetic neuralgia. Though, opioid usage remained untouched across all the groups, with gabapentin giving lesser pain relief to people who used opioids. This study suggests that gabapentin might be an effective drug for neuropathic pain treatment, especially in postherpetic neuralgia.

According to this study[39], they attempted to determine could gabapentin effectively treat spinal cord injury caused neuropathic pain. Already available information emphasised the difficulty in the treatment of neuropathic pain due to nervous system failure, specially in case of spinal cord injury, where there is no effective current treatment. Gabapentin, is regularly used for treatment of neuropathic pain, hasn't been fully examined for this specific disease. The 18-week trial included a careful protocol, which included titration periods and steady dosing, with 20 patients who misfortunately had been suffering from spinal cord injury caused neuropathic pain for greater than six months period. Gabapentin was found to effective in reducing pain intensity and frequency, thus improving quality of life, and also relieve a variety of neuropathic pain features. In conclusion study found that Gabapentin can be considered first line drug for spinal cord injury pain.

According to this study[40], Pregabalin, amitriptyline, and gabapentin were compared for treating cancer caused neuropathic pain in 120 patients with approval from Institutional ethics committee . Pregabalin reduced the pain scores considerably greater than other drugs, mainly lancinating pain and dysesthesia. Patients on pregabalin required less rescue morphine and confirmed the most improvement in functional and satisfaction scores. The conclusions reflect to pregabalin's better effectiveness in treating neuropathic cancer pain.

In this study[41], Many anticonvulsants, like gabapentin and pregabalin are recommended for management of neuropathic pain, but slight is known about their clinical differences in cases of lower back pain. This study aims to shed light on some of the clinical differences between gabapentin and pregabalin in lower back pain. Patients with moderate to severe lower back pain were part of this study and were randomly given either pregabalin (300 mg/day)or gabapentin (800 mg/day) for time period of six weeks. The primary outcome measure was pain intensity according to the Visual Analogue Score (VAS) at baseline and at six weeks. The secondary outcome measures were: anxiety, insomnia, fatigue and the self-rated (GCI), measured at baseline, second, fourth, and the sixth week. A total of 64 patients, pregabalin group (n=28), gabapentin group (n=36) were in the study. While pregabalin group displayed a significantly lower pain score (p=0.039). The gabapentin group showed important improvement in anxiety (p=0.001), insomnia (p=0.001), general fatigue (p=0.009), physical fatigue (p=0.001), reduce activity (p=0.001), and mental fatigue (p=0.014) higher than that of pregabalin. No difference in (GCI) Was seen at six weeks.
In conclusion pregabalin was found to be larger in pain reduction, gabapentin confirmed better effect on anxiety, insomnia and fatigue symptoms.

According to this study[42], Pregabalin and gabapentin are widely used in neurology, psychiatry and primary healthcare but are increasingly being reported as possessing a potential for misuse. Increase of prescriptions and

related fatalities, together with also growing black market, have been reported from many countries. This study reviews the evidence for this potential, misuse of these drugs. Pregabalin has by higher potency, quicker absorption rates and greater bioavailability levels than gabapentin. Although at therapeutic dosages gabapentinoids may present with low addictive liability levels, misusers' perceptions for these molecules to constitute a valid substitute for most common illicit drugs may be a reason of concern. Gabapentinoid misusers are profiled here as individuals with a history of recreational polydrug misuse. Physicians considering prescribing gabapentinoids for neurological/psychiatric disorders should carefully evaluate a possible previous history of drug abuse, whilst being able to promptly identify signs of pregabalin/gabapentin misuse and provide possible assistance in tapering off the medication.

According to this study[43], Gabapentin (Neurontin) and Pregabalin's mechanism of action is not yet fully understood, but research has demonstrated promising results. They also have been used in combination in clinical as well as research situations, and there has been observed a synergistic effect in pain control without concern for clinically significant drug interactions. This combined approach can be made use of to reduce the dosage of individual drug, its side effects, and to enhance therapeutic response compared to a single agent. Pharmacokinetics, drug interactions, and adverse reaction to combinations have to be taken into consideration before combination therapy with Gabapentin and Pregabalin is purported as first line treatment in refractory pain situations and in patients with low levels of tolerance for individual agent.

According to this study[44], motive was to compare different combinations of amitriptyline, pregabalin and duloxetine, for treating Diabetic peripheral neuropathic pain. Patients from 13 UK centres had participated and were randomly assigned to one of six treatment sequences. Every sequence had lasted 16 weeks, with allowing participants to switch between drugs based on pain relief. The primary goal was to see which combination reduced pain the most. In time period Nov 2017 and July 2019, 130 patients started a treatment, with 84 completing at least two. All three combinations lead to reduction of pain similarly, and combination therapy was generally well-tolerated and effective. Still, some patients experienced side effects like dizziness, nausea, and dry mouth. In conclusion, our study, the largest of its kind, found that all three treatment pathways were equally effective in reducing DPNP. Combination therapy may offer better pain relief for those not responding well to monotherapy.

4. EFFECT OF PREGABLIN, GABAPENTIN AND AMITRIPTYLINE IN SCIATICA AND ORTHOPAEDIC BACKPAIN PATIENTS

4.1 STUDIES AND CLINICAL TRIALS

In outpatient settings, lumbar disc herniation (LDH) is a problem that is commonly observed. It entails the intervertebral disc constituents moving outside of their typical range. Parts of the annulus fibrosus, nucleus pulposus, or both may be included in this group of disc components. These materials can cause pain in the leg and lower back when they become displaced and push on nerve roots and the cauda equina.

Hiroaki Nakashima et. al conducted a study – "Is Pregabalin is Effective Against Acute Lumbar Radicular Pain ?" and they concluded that Combining NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Pregabalin is more effective at reducing sleep disturbances than using NSAIDs alone in patients with acute Lumbar Disc Herniation (LDH). While this combination has a minimal effect on managing sciatic pain, patients still reported satisfactory recovery outcomes. Thus, this therapeutic approach may be a valuable option for the conservative treatment of acute lumbar radicular pain, including lumbar disc herniation(LDH).[45]

Dr. Akashdeep Singh et. al conducted a study - "the comparison of functional outcomes between pregabalin versus gabapentin in Cases of Low Back Ache with radiculopathy". They appointed 100 patients having lower back ache with radiculopathy. All 100 patients were divided in 2 groups. First group consists of 50 patients – Gabapentin Group and the second group consisting of remaining 50 patients – Pregabalin Group . Pregabalin was used in form of capsule 75 mg ,Gabapentin was used in form of tablet 300 mg. Both these drugs were given one time a day at night. They recorded pain intensity at initial point of study, later after 1 month and 3 months by using VAS. The SPSS software was used to record the results. They concluded that Gabapentin was known to be better in manner of having less side effects than pregabalin.[46]

Two trials examined the impact of anticonvulsants on patients with chronic sciatica symptoms. In one crossover study, topiramate (50-400 mg/day) did not demonstrate any immediate improvement over placebo in terms of disability and leg or back pain. Conversely, another study found that gabapentin (900-3600 mg) provided significant short-term pain relief.[47]

Jacoline J van den Driest et. al conducted a study reviewing Amitriptyline for musculoskeletal complaints. In this study they used controlled randomised trials on amitriptyline in musculoskeletal complaints in comparison to placebo. Pain relief and improved function were the main outcomes of interest. From this study they concluded that Based on data from other disorders, amitriptyline can be used for chronic musculoskeletal conditions. Even with the small number of studies, amitriptyline may help individuals with musculoskeletal problems feel better about their pain and function. Comparing to other analgesics, nevertheless, could not result in noticeably superior pain relief. To identify the precise ailments and patient populations for which amitriptyline may be more beneficial than other painkillers, hence more investigation is required.[48]

For those who have suffered a spinal cord injury (SCI), chronic pain is a challenging issue for which there is no easy treatment. There haven't been many randomized controlled studies of drugs for pain in people with spinal cord injury. Diana D. Cardenas et.al conducted a study for amitriptyline for relief of pain in spinal cord injury. They concluded that No significant differences in pain intensity or pain-related disability were observed between the groups after treatment, whether in intent-to-treat analyses or analyses of study completers. These results do not support the use of amitriptyline for treating chronic pain in the patients who require relieve in chronic pain and improving pain-related physical and psychosocial dysfunction with spinal cord injury[49]

Despite the limited data, the UK National Institute for Health and Clinical Excellence preferred pregabalin over gabapentin due to minor titration advantages and cost considerations. However, without clear evidence supporting the interchangeability of pregabalin and gabapentin, neither drug should be definitively favoured. There is a pressing need for prospective "head-to-head" studies to provide strong, evidence-based guidance on choosing between gabapentin and pregabalin for sciatica treatment.[50]

The evidence for using 25 mg of amitriptyline for the short-term therapy of fibromyalgia symptoms is, at best, modest or perhaps poor, despite the medication's persistent effectiveness. The clinical importance of these findings remains uncertain. Amitriptyline should not be used for longer than eight weeks or at greater doses without evidence.[51]

For many years, amitriptyline has been the primary treatment for fibromyalgia. Although it is disheartening, the lack of robust objective data supporting its positive impact must be balanced against the years of successful outcomes reported by many fibromyalgia patients. Our concern should be more about the potential overestimation of treatment effects rather than the absence of evidence. Given that only a small proportion of patients may experience significant pain relief, amitriptyline remains a treatment option for fibromyalgia. It is unlikely that large-scale randomized studies on the use of amitriptyline in fibromyalgia patients will be conducted to determine its statistical efficacy or measure the extent of its effect.[52]

It's still unknown what the best pharmacologic course of action is for chronic sciatica. Equipoise exists even though gabapentin and pregabalin are also used to treat chronic sciatica. However, pharmaceutical regulatory bodies usually choose to support one medication over the different. This prevents switching when the preferred medication is unsuccessful or poorly tolerated. Randomised clinical trial study conducted by Kelvin Robertson et. al Both gabapentin and pregabalin demonstrated significant efficacy. Gabapentin was better, though, with fewer and milder adverse effects. It is best to start gabapentin before pregabalin to allow for the best possible medication crossover.[53]

International professional recommendations advise against using antidepressants for the treatment of chronic low back pain, even at modest doses . But there isn't any proof of their effectiveness. Clinical trial conducted by Donna M. Urquhart et. al. suggests that amitriptyline may be a useful medication for treating persistent low back pain. A decrease in impairment was noted at three months, and there was a nonsignificant improvement in pain intensity at six months, despite the fact that there were no significant improvements in the outcomes at six months. When a low-dose regimen was used with a tiny sample size and an active comparator, very few side events were documented. Although large-scale clinical trials with dose escalation are required, low-dose amitriptyline may be an option if opioids are the only other available treatment.[54]

5. CONCLUSION

Gabapentin, amitriptyline, and pregabalin are all valuable options for managing back pain of neurological, sciatica, and orthopedic origin. The choice of medication should be tailored to the individual patient, considering the specific pain characteristics, patient preferences, and potential side effects. Regular monitoring and adjustment of dosages are recommended to optimize treatment outcomes and minimize adverse effects. Gabapentin and Pregabalin These two medications are often

favoured for their efficacy in treating neuropathic pain, including conditions like sciatica. Pregabalin might be preferred slightly more due to its favourable side effect profile and rapid onset of action. Both are commonly prescribed in neurological and orthopedic settings due to their effectiveness in managing nerve pain. Amitriptyline is often used less frequently as a first-line treatment compared to gabapentin and pregabalin, primarily due to its side effect profile. It is, however, a valuable option for patients who also benefit from its antidepressant and sleep-enhancing properties.

6. ACKNOWLEDGEMENT

No Acknowledgement to declare

7. REFERENCE

[1]. Patel, V., et al., Disease control priorities, (volume 4): mental, neurological, and substance use disorders. 2016: World Bank Publications.
[2]. Zis, P. and M. Hadjivassiliou, Treatment of neurological manifestations of gluten sensitivity and coeliac disease. Current treatment options in neurology, 2019. 21: p. 1-10.
[3]. Attal, N., et al., EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European journal of neurology, 2010. 17(9): p. 1113-e88.
[4]. Moore, J. and C. Gaines, Gabapentin for chronic neuropathic pain in adults. British Journal of Community Nursing, 2019. 24(12): p. 608-609.
[5]. Risher, W.C. and C. Eroglu, Emerging roles for α2δ subunits in calcium channel function and synaptic connectivity. Current opinion in neurobiology, 2020. 63: p. 162-169.
[6]. NICE, C.f.C.P.a., Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings [Internet]. 2013.
[7]. Moulin, D., et al., Pharmacological management of chronic neuropathic pain–consensus statement and guidelines from the Canadian Pain Society. Pain Research and Management, 2007. 12: p. 13-21.
[8]. Shanthanna, H., et al., Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. PLoS medicine, 2017. 14(8): p. e1002369.
[9]. Finnerup, N.B., et al., Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. The Lancet Neurology, 2015. 14(2): p. 162-173.
[10]. Geldenhuys, W.J., et al., Molecular determinants of blood–brain barrier permeation. Therapeutic delivery, 2015. 6(8): p. 961-971.
[11]. Dickens, D., et al., Transport of gabapentin by LAT1 (SLC7A5). Biochemical pharmacology, 2013. 85(11): p. 1672-1683.
[12]. Bockbrader, H.N., et al., A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clinical pharmacokinetics, 2010. 49: p. 661-669.
[13]. Hariman, C., Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. 2022.
[14]. Sills, G.J., The mechanisms of action of gabapentin and pregabalin. Current opinion in pharmacology, 2006. 6(1): p. 108-113.
[15]. Calandre, E.P., F. Rico-Villademoros, and M. Slim, Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert review of neurotherapeutics, 2016. 16(11): p. 1263-1277.
[16]. Onakpoya, I.J., et al., Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ open, 2019. 9(1): p. e023600.
[17]. Drug Enforcement Administration, D.o.J., Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Federal register, 2005. 70(144): p. 43633-43635.
[18]. Slocum, G.W., et al., Pregabalin and paradoxical reaction of seizures in a large overdose. Toxicology Communications, 2018. 2(1): p. 19-20.
[19]. Bandelow, B., et al., Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care. International journal of psychiatry in clinical practice, 2012. 16(2): p. 77-84.
[20]. Millar, J., et al., Lyrica nights–recreational pregabalin abuse in an urban emergency department. Emergency Medicine Journal, 2013. 30(10): p. 874-874.

[21]. FDA, D., FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). United States: FDA, 2019.
[22]. Tanyıldız, B., et al., Bilateral serous macular detachment after attempted suicide with pregabalin. Turkish Journal of Ophthalmology, 2018. 48(5): p. 254.
[23]. Jetli, S., A. Verma, and H. Sharma, A comparative study on efficacy and safety for management of neuropathic pain with gabapentin, pregabalin, and amitriptyline. Pakistan J Med Heal Sci, 2021. 15(9): p. 2995-8.
[24]. Chahine, B. and F. Al Souheil, Dispensing patterns of drugs used for neuropathic pain and adherence to NeuPSIG guideline: an observational study. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021. 57: p. 1-8.
[25]. Singh, V.K., et al., Prescription pattern of drugs used for neuropathic pain and adherence to NeuPSIG guidelines in cancer. Indian Journal of Palliative Care, 2020. 26(1): p. 13.
[26]. Ashworth, J., et al., Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study. The Lancet Regional Health–Europe, 2023. 27.
[27]. Euasobhon, P., et al., Incidence and treatment strategies of neuropathic pain: the tertiary care setting's experience. Siriraj Med J, 2013. 65: p. 123-7.
[28]. Berger, A., et al., Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study. BMC neurology, 2012. 12: p. 1-13.
[29]. Zaccara, G., P. Perucca, and P.F. Gangemi, The adverse event profile of pregabalin across different disorders: a meta-analysis. European journal of clinical pharmacology, 2012. 68: p. 903-912.
[30]. Freynhagen, R., et al., Pregabalin for neuropathic pain in primary care settings: recommendations for dosing and titration. Postgraduate Medicine, 2021. 133(1): p. 1-9.
[31]. Zaccara, G., et al., The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials. Epilepsia, 2011. 52(4): p. 826-836.
[32]. Bonnet, U. and N. Scherbaum, How addictive are gabapentin and pregabalin? A systematic review. European neuropsychopharmacology, 2017. 27(12): p. 1185-1215.
[33]. Viñas-Bastart, M., et al., Clinical use of pregabalin in general practice in Catalonia, Spain: a population-based cross-sectional study. Pain Medicine, 2018. 19(8): p. 1639-1649.
[34]. Gustavsson, A., et al., Pharmacological treatment patterns in neuropathic pain—lessons from Swedish administrative registries. Pain Medicine, 2013. 14(7): p. 1072-1080.
[35]. Jacob, L., M. Kaiser, and K. Kostev, Incidence of antiepileptic drug therapy and factors associated with their prescribing in outpatients with diabetic polyneuropathy. Primary Care Diabetes, 2021. 15(3): p. 535-540.
[36]. Machado-Duque, M.E., et al., Evaluation of treatment patterns and direct costs associated with the management of neuropathic pain. Pain Research and Management, 2020. 2020.
[37]. Bennett, M.I. and K.H. Simpson, Gabapentin in the treatment of neuropathic pain. Palliative Medicine, 2004. 18(1): p. 5-11.
[38]. Rosenberg, J.M., et al., The effect of gabapentin on neuropathic pain. The Clinical journal of pain, 1997. 13(3): p. 251-255.
[39]. Levendoglu, F., et al., Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine, 2004. 29(7): p. 743-751.
[40]. Mishra, S., et al., A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. American Journal of Hospice and Palliative Medicine®, 2012. 29(3): p. 177-182.
[41]. Gammoh, O., et al., The clinical difference between gabapentin and pregabalin: data from a pilot comparative trial. Reviews on Recent Clinical Trials, 2021. 16(3): p. 279-287.
[42]. Schifano, F., Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS drugs, 2014. 28(6): p. 491-496.
[43]. Senderovich, H. and G. Jeyapragasan, Is there a role for combined use of gabapentin and pregabalin in pain control? Too good to be true? Current medical research and opinion, 2018. 34(4): p. 677-682.
[44]. sfaye, S., et al., Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised cr
[45]. Nakashima, H., Kanemura, T., Ando, K., Kobayashi, K., Yoneda, M., Ishiguro, N. and Imagama, S., 2019. Is pregabalin effective against acute lumbar radicular pain?. Spine Surgery and Related Research, 3(1), pp.61-66.

[46]. Singh, A., Aggarwal, S. and Behal, T., 2021. To study the comparison of functional outcomes between pregabalin versus gabapentin in Cases of Low Back Ache with radiculopathy. European Journal of Molecular and Clinical Medicine, 8(4), pp.1872-1876.

[47]. Pinto, R.Z., Maher, C.G., Ferreira, M.L., Ferreira, P.H., Hancock, M., Oliveira, V.C., McLachlan, A.J. and Koes, B., 2012. Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis. Bmj, 344.

[48]. van den Driest, J.J., Bierma-Zeinstra, S.M., Bindels, P.J. and Schiphof, D., 2017. Amitriptyline for musculoskeletal complaints: a systematic review. Family Practice, 34(2), pp.138-146.

[49]. Cardenas, D.D., Warms, C.A., Turner, J.A., Marshall, H., Brooke, M.M. and Loeser, J.D., 2002. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain, 96(3), pp.365-373.

[50]. Robertson, K., Marshman, L.A. and Plummer, D., 2016. Pregabalin and gabapentin for the treatment of sciatica. Journal of Clinical Neuroscience, 26, pp.1-7.

[51]. Nishishinya, B., Urrútia, G., Walitt, B., Rodriguez, A., Bonfill, X., Alegre, C. and Darko, G., 2008. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology, 47(12), pp.1741-1746.

[52]. Moore, R.A., Derry, S., Aldington, D., Cole, P., Wiffen, P.J. and Cochrane Pain, Palliative and Supportive Care Group, 1996. Amitriptyline for fibromyalgia in adults. Cochrane Database of Systematic Reviews, 2019(5).

[53]. Robertson, K., Marshman, L.A., Plummer, D. and Downs, E., 2019. Effect of gabapentin vs pregabalin on pain intensity in adults with chronic sciatica: a randomized clinical trial. JAMA neurology, 76(1), pp.28-34.

[54]. Urquhart, D.M., Wluka, A.E., Van Tulder, M., Heritier, S., Forbes, A., Fong, C., Wang, Y., Sim, M.R., Gibson, S.J., Arnold, C. and Cicuttini, F.M., 2018. Efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial. Jama internal medicine, 178(11), pp.1474-1481.

ossover trial. The Lancet, 2022. 400(10353): p. 680-690.